If these hurdles can be overcome, PD-1/PARP combinations may evolve from a promising niche approach to a targeted standard of care for biomarker-selected patients with advanced gynecological cancers, improving long-term survival and bringing the field closer to truly personalized, immune-driven oncology for women worldwide. This evidence concerns the gene PDCD1 and female reproductive organ cancer.